We research interventions to improve public acceptability and uptake of cancer screening, especially in deprived populations
We study ways of optimising the benefits and minimising the human and resource costs of screening programmes
We work on development and testing of screening technologies for new programmes
We study the progression of cancer to identify optimum times and methods to stop this progression by early detection and prompt treatment
We generate evidence on screening intervals, the benefits and harms of screening at different ages, and reasons for differences in screening performance
We research risk-based intervals and the potential for personalised screening regimens
We study technologies with the potential to improve existing screening programmes
Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncol (2020) 21(9):1165-1172. PMID: 32800099
A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. Int J Cancer (2020) 146(8):2122-2129. PMID: 31251818
A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncol (2019) 5(12):1718-1730. PMID: 31580391
Molecular progression to cervical precancer, epigenetic switch or sequential model? Int J Cancer (2018) doi: 10.1002/ijc.31549. PMID: 29679470
Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol (2017) 18(6):823-834. PMID: 28457708
The effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial. Lancet Oncology (2017) 18(7):972-980. PMID: 28522311
Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol (2017) 18(6):823-834. PMID: 28457708
Optimum low does CR screening interval for lung cancer: the answer from NELSON?. Thorax (2017) 72(1):6-7. PMID: 27974632
Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Thorax (2017) 72(10):912-918. PMID: 28710339
Barriers to HPV self-sampling and cytology among low-income indigenous women in rural areas of a middle-income setting: a qualitative study. BMC Cancer (2017) 17(1):734. PMID: 29121873
Genotyping for Human Papillomavirus types 16 and 18 in women with minor cervical lesions: A systematic review and meta-analysis. Ann Intern med (2017) 166(2):118-127. PMID: 27842420
Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol (2017) 3(6):833-837. PMID: 27685805
Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer (2016) 138(11):2745-51. PMID: 26790008
A DNA methylation classifier of cervical pre-cancer based on human papilloma virus and human genes. Int J Cancer (2014) 135(6):1425-32. PMID: 24535756
HPV16 L1 and L2 DNA methylation predicts high grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer (2013) 133(3):637-44. PMID: 23335178